Document is current
Any future updates will be listed below
-
Authors
Chen, Bolin
Yao, Wenxiu
Li, Xingya
Lin, Gen
Chu, Qian https://orcid.org/0000-0001-8192-7630
Liu, Hailong
Du, Yingying
Lin, Jie
Duan, Huaxin
Wang, Huijuan
Xiao, Zemin
Sun, Hong
Liu, Liyu
Xu, Li
Xu, Yan
Xu, Fang
Kong, Yi
Pu, Xingxiang
Li, Kang
Wang, Qianzhi
Li, Jia
Li, Baiyong
Xia, Yu
- License Information
-
More Information
Article History
Received: 10 April 2023
Revised: 15 November 2023
Accepted: 23 November 2023
First Online: 18 December 2023
Ethics approval and consent to participate
: This study was approved by the ethics committee of Hunan Cancer Hospital (approval number: 2018L02552) and the institutional review boards or independent ethics committees of all other participating centers. The trial was conducted in accordance with the International Conference on Good Clinical Practice Standards and the Declaration of Helsinki. All patients provided written informed consent before study participation.
: LW reported personal fees from AstraZeneca, Roche, Bristol-Myers Squibb, MSD, Pfizer, Lilly, Johnson and Johnson, GSK, Bayer, Sanofi, Boehringer Ingelheim, Merck, Innovent, and Hengrui outside the submitted work. No disclosures were reported by the other authors.
